Turmeric Acquisition Corp.

General Information

We intend to capitalize on the ability of our management team to identify promising opportunities in the biotechnology sector, with an emphasis on oncology and rare disease therapeutics where our management has extensive experience in investing, operating and drug development.

Our founder and CEO is Luke Evnin of MPM Capital in Cambridge, Massachusetts. MPM Capital is an affiliate of our sponsor, Turmeric Management, LLC.

Luke Evnin, Ph.D., has more than 30 years of experience in healthcare investing. He is a co-founder and managing director of MPM Capital. Mr. Evnin co-founded MPM in 1997 with Ansbert Gadicke, M.D., and opened the San Francisco office in 1999. Mr. Evnin’s passion for discovering and advancing groundbreaking drug discovery companies inspires his work and that of the MPM team, which has been the driving force behind building companies such as BioMarin Pharmaceutical, CoStim Pharmaceuticals (acquired by Novartis), Epizyme, Idenix Pharmaceuticals (acquired by Merck), Idun Pharmaceuticals (acquired by Pfizer), Pacira Pharmaceuticals, Pharmasset (acquired by Gilead), Potenza Therapeutics (acquired by Astellas Pharma) and Radius Health


Employees: 0
Founded: 2020
Contact Information
Address 450 Kendall St Cambridge, MA 02142
Phone Number 617 425 9200
Web Address
View Prospectus: Turmeric Acquisition Corp.
Financial Information
Market Cap $110.2mil
Revenues $0 mil (last 12 months)
Net Income $0 mil (last 12 months)
IPO Profile
Symbol TMPMU
Exchange NASDAQ
Shares (millions): 8.5
Price range $10.00 - $10.00
Est. $ Volume $85.0 mil
Manager / Joint Managers Credit Suisse/ JMP Securities
Expected To Trade: 10/16/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change